NCT06975787View on ClinicalTrials.gov

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

November 6, 2025

Primary Completion Date

July 13, 2028

Study Completion Date

July 13, 2028

Conditions

Lupus Nephritis (LN)

Interventions

DRUG

Vonsetamig

Administered as per the protocol

DRUG

Odronextamab

Administered as per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY